Detection, quantitation, and genotyping of human papillomavirus circulating tumor DNA by droplet digital PCR
At least 14 genotypes of human papillomavirus (HPV) have been identified to have high oncogenic potential. While molecular diagnostic testing for HPV is widely available for liquid cytologic cervical samples, testing is limited for other sample types, including liquid biopsy samples, such as platelet-poor plasma (PPP). With the rising incidence of HPV-associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC), laboratory testing is an essential part of patient diagnosis, management, and surveillance. Here, we summarize the development and analytical performance validation of a multiplexed, droplet digital PCR (ddPCR) assay for the detection and quantitation of HPV circulating tumor DNA (ctDNA) in PPP. This assay may provide clinicians with a tool to address minimal residual disease for patients with an HPV-associated cancer.
Authors
- Matthew J. Binnicker (ORCID: https://orcid.org/0000-0003-2537-7165)
- Danielle E. Hunter
- James S. Lewis (ORCID: https://orcid.org/0000-0001-9002-1283)
- Eric J. Moore (ORCID: https://orcid.org/0000-0003-1103-6212)
- Kathryn M. Van Abel (ORCID: https://orcid.org/0000-0003-0513-4203)
- Erik Wendlandt
- David M. Routman (ORCID: https://orcid.org/0000-0002-2768-003X)
- Emily C. Fernholz (ORCID: https://orcid.org/0000-0002-9300-4451)
- Kathleen R. Bartemes (ORCID: https://orcid.org/0000-0003-4561-3233)
- Jeannie Daniel
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Integrated DNA Technologies (United States) (US)
Publication Details
- Journal
- Journal of Clinical Microbiology
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1128/jcm.00585-25
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00